- Trials with a EudraCT protocol (207)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
207 result(s) found for: Juvenile Onset Diabetes Mellitus AND Type 1 Diabetes.
Displaying page 9 of 11.
EudraCT Number: 2009-012988-34 | Sponsor Protocol Number: NI-0401-04 | Start Date*: 2009-10-19 | |||||||||||
Sponsor Name:NovImmune SA | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled clinical trial investigating the safety and efficacy of NI-0401 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D) | |||||||||||||
Medical condition: Preservation of beta (β)-islet cell function in patients newly diagnosed with Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005774-13 | Sponsor Protocol Number: NN1250-3583 | Start Date*: 2009-07-24 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 52 week randomised, controlled, open label, multicentre, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in ... | |||||||||||||
Medical condition: type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005769-71 | Sponsor Protocol Number: NN5401-3594 | Start Date*: 2009-07-09 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week, multinational, multi-centre, open-labelled, two-arm, parallel, randomised, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) once daily p... | |||||||||||||
Medical condition: type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015755-24 | Sponsor Protocol Number: NN1250-3644 | Start Date*: 2010-04-08 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: An extension trial to trial NN1250-3583 comparing safety and efficacy of NN1250 with insulin glargine, both with insulin aspart as meal-time insulin, in type 1 diabetes | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013412-13 | Sponsor Protocol Number: NN5401-3645 | Start Date*: 2009-12-02 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: An extension trial comparing safety and efficacy of NN5401 plus meal-time insulin aspart for the remaining meals with insulin detemir plus meal-time insulin aspart in type 1 diabetes | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000821-35 | Sponsor Protocol Number: RUNMC-GLP1-TRANSPL-2015 | Start Date*: 2015-09-22 | ||||||||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||||||||||||
Full Title: Visualizing beta cells after Intrahepatic Islet of Langerhans Transplantation | ||||||||||||||||||||||||||||
Medical condition: Intrahepatic islet transplantation in type 1 diabetes patients | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003006-33 | Sponsor Protocol Number: RUNMC-GLP1-EX-GELO-2014 | Start Date*: 2015-02-16 | ||||||||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||||||||||||
Full Title: Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 uptake in the kidney | ||||||||||||||||||||||||||||
Medical condition: The aim of this study is to reduce the kidney uptake during 111In-DTPA- exendin4 imaging, a promising and valuable tool for beta-cell mass imaging and quantification, which can be applied in patien... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003265-17 | Sponsor Protocol Number: S63466 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Universitair Ziekenhuis Leuven (UZ Leuven) | |||||||||||||
Full Title: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D) | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FI (Completed) SI (Completed) AT (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000770-29 | Sponsor Protocol Number: Ireland-RctV8 | Start Date*: 2018-06-18 | ||||||||||||||||
Sponsor Name:The Rotunda Hospital | ||||||||||||||||||
Full Title: Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of low-dose aspirin initiated in the first trimester of diab... | ||||||||||||||||||
Medical condition: Pregestational type I or type II diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002457-69 | Sponsor Protocol Number: CP-MGA031-01 | Start Date*: 2008-12-04 | |||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-C... | |||||||||||||
Medical condition: Recent-onset type I diabetes mellitus (T1DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SE (Completed) GB (Completed) EE (Completed) NL (Completed) LV (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004731-29 | Sponsor Protocol Number: NN1998-1617 | Start Date*: 2007-06-07 | |||||||||||||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||||||||||||
Full Title: Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and chronic obstructive pulmonary disease: A 52-week, open-label, multice... | |||||||||||||||||||||||
Medical condition: Type 1 Diabetes Type 2 Diabetes COPD | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000435-45 | Sponsor Protocol Number: Ver-A-T1D | Start Date*: 2021-03-24 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preser... | |||||||||||||
Medical condition: Type 1 diabetes mellitus(T1DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001317-20 | Sponsor Protocol Number: IMCY-T1D-003 | Start Date*: 2020-09-11 | |||||||||||
Sponsor Name:Imcyse SA | |||||||||||||
Full Title: A Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect ... | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SI (Completed) LT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004622-81 | Sponsor Protocol Number: NN1998-1616 | Start Date*: 2007-11-02 | |||||||||||||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||||||||||||
Full Title: Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: a 52-week, open-label, multinational, randomised, parallel tr... | |||||||||||||||||||||||
Medical condition: Type 1 diabetes Type 2 diabetes Asthma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005256-26 | Sponsor Protocol Number: 1245.72 | Start Date*: 2015-12-23 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 2... | |||||||||||||
Medical condition: Patients with confirmed, insulin-dependent type 1 diabetes mellitus for at least 1 year | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (Completed) FI (Completed) IE (Completed) LV (Completed) NL (Completed) HU (Completed) PT (Completed) GR (Completed) FR (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003579-38 | Sponsor Protocol Number: APIDR_C_02083 | Start Date*: 2007-11-13 | |||||||||||
Sponsor Name:sanofi-aventis groupe | |||||||||||||
Full Title: Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Dia... | |||||||||||||
Medical condition: Type I Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SE (Completed) NL (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004966-20 | Sponsor Protocol Number: 20201013 | Start Date*: 2021-08-05 | |||||||||||
Sponsor Name:Radboud University Medical Center | |||||||||||||
Full Title: A GLP-1 receptor PET imaging add-on study within the Ver-A-T1D trial investigating the effects of Verapamil or placebo on beta cell mass (ImageVer-A-T1D) | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024049-53 | Sponsor Protocol Number: NN1218-3852 | Start Date*: 2013-07-16 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) CZ (Completed) GB (Completed) DE (Completed) PL (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000747-32 | Sponsor Protocol Number: MYL-GAI-3001 | Start Date*: 2014-08-27 | |||||||||||
Sponsor Name:MYLAN GmbH | |||||||||||||
Full Title: AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS | |||||||||||||
Medical condition: Type 1 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) CZ (Completed) DE (Completed) GB (Completed) EE (Completed) HU (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002775-17 | Sponsor Protocol Number: 1010 | Start Date*: 2013-10-29 | |||||||||||
Sponsor Name:Andromeda Biotech Ltd | |||||||||||||
Full Title: OPEN-LABEL STUDY TO EVALUATE LONG TERM SAFETY AND TREATMENT EFFECT OF DIAPEP277® IN SUBJECTS WHO HAVE COMPLETED STUDY 1001 | |||||||||||||
Medical condition: Type I diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
